Welcome to our dedicated page for Vicarious Surgical SEC filings (Ticker: RBOT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vicarious Surgical Inc. (RBOT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a public surgical robotics and medical device developer. These filings offer detailed information on the Vicarious Surgical System, the company’s operating expenses, capital structure, governance and listing status.
Through annual reports on Form 10-K and quarterly reports on Form 10-Q, Vicarious Surgical presents audited and interim financial statements, segment information for research and development, sales and marketing, and general and administrative activities, along with risk factors and management’s discussion of its development-stage business. Current reports on Form 8-K disclose material events such as registered direct offerings and private placements of common stock and warrants, at-the-market offering agreements, cash burn guidance, board and committee changes, and special meetings of stockholders to approve warrant exercises under New York Stock Exchange rules.
Filings also document listing and registration matters. For example, a Form 25 filed by the New York Stock Exchange relates to the removal from listing and registration of Vicarious Surgical’s publicly traded warrants, while separate 8-K items describe the NYSE’s notice to commence delisting proceedings for those warrants and the continued listing of the company’s Class A common stock under the symbol RBOT, subject to compliance with NYSE standards.
On Stock Titan, these documents are supplemented by AI-powered summaries that explain the key points of lengthy filings, such as complex financing terms, warrant structures, or at-the-market programs. Users can quickly see highlights from 10-K and 10-Q reports, understand the implications of Form 8-K events, and review proxy materials like definitive proxy statements (DEF 14A) that cover special meetings and stockholder proposals. The page also links to information about warrants, capital raises and other securities-related disclosures, helping investors and researchers analyze how Vicarious Surgical funds and governs the development of its single-port robotic surgery platform.
Vicarious Surgical Inc. reported the results of a special stockholder meeting held on January 9, 2026. Stockholders voted on a single proposal related to warrants previously issued by the company.
Holders of Class A and Class B common stock, voting together as a single class, approved the exercise of warrants issued on October 7, 2025 to purchase up to an aggregate of 2,300,000 shares of Class A common stock. The proposal passed with 14,991,093 votes in favor, 23,052 votes against, and 2,894 abstentions.
There were 2,591,229 shares of Class A and Class B common stock present or represented by proxy at the meeting, representing approximately 78.18% of the outstanding total voting power entitled to vote, which was sufficient to constitute a quorum.
Vicarious Surgical Inc. is offering up to $3,000,000 of Class A common stock through an at-the-market program under an existing $100,000,000 shelf registration. The shares will be sold from time to time on the New York Stock Exchange or other U.S. trading markets through H.C. Wainwright & Co. as sales agent or principal, earning a 3.0% commission on gross proceeds. Based on a recent NYSE price of $2.17, this would represent up to 1,382,488 shares, with total Class A shares outstanding potentially rising to 7,845,739, though actual issuance will depend on future trading prices and sale decisions.
The company plans to use any net proceeds for general corporate purposes, including working capital, capital spending, and research and development or clinical trial costs, and may also fund possible acquisitions or strategic investments. Vicarious Surgical is developing a single-port robotic surgical system that has not yet been authorized by the FDA and remains in a pre-commercial, development-focused stage. The company has an NYSE compliance plan in place after previously falling below market capitalization and equity listing thresholds, and warns that investors face significant risks, including dilution and share price volatility.
Vicarious Surgical Inc. is having its warrants removed from listing and registration on the New York Stock Exchange under Section 12(b) of the Securities Exchange Act of 1934. The notification is made on SEC Form 25, with the Exchange certifying it has reasonable grounds to file.
The affected security is described as warrants, with each whole warrant exercisable for 1/30th of a share of Class A common stock at an exercise price of $345.00. The New York Stock Exchange states it has complied with its rules to strike this class of securities, and that the issuer has complied with exchange and SEC requirements for the voluntary withdrawal of this class from listing and registration.
Vicarious Surgical Inc. entered into an at-the-market offering agreement with H.C. Wainwright & Co., allowing the company to sell shares of its Class A common stock from time to time through the sales agent, subject to a new Form S-3 shelf registration statement becoming effective. The ATM prospectus supplement currently permits sales of shares with an aggregate market value of
The company will pay Wainwright a
Vicarious Surgical Inc. has called a special stockholder meeting on January 9, 2026 to vote on allowing the exercise of Common Warrants issued on October 7, 2025. These warrants give an institutional investor the right to buy up to 2,300,000 shares of Class A common stock at an exercise price of $5.10 per share, but they are not exercisable until stockholders approve their exercise under New York Stock Exchange rules.
The company previously raised about $5.9 million in gross proceeds in an October 2025 registered direct offering and concurrent private placement. As of September 30, 2025, it held roughly $3.2 million in cash and $10.3 million in short‑term investments. If the proposal is approved and all warrants are exercised for cash, Vicarious Surgical could receive up to approximately $11.7 million in additional gross proceeds, while existing holders would face dilution as up to 2,300,000 new shares become issuable. The board of directors unanimously recommends voting “FOR” the proposal.
Vicarious Surgical Inc. has filed a shelf registration statement allowing it to offer up to $100,000,000 of Class A common stock, preferred stock, debt securities, warrants, rights and units over time. A separate sales agreement prospectus covers an at-the-market program for up to $3,000,000 of Class A common stock through H.C. Wainwright & Co., which is included within the $100 million capacity.
The company develops a next-generation single-port robotic surgical system that has not yet been authorized by the FDA; it targets a clinical-ready system by mid‑2026, design freeze by the end of 2026, and first‑in‑human trials in 2027, subject to regulatory clearance. Net proceeds from any future sales may be used for general corporate purposes such as working capital, capital expenditures, research and development, and potential acquisitions. Vicarious Surgical also discloses an NYSE compliance plan after falling below the $50 million minimum market capitalization and warns that failure to regain compliance within the 18‑month cure period could lead to suspension and delisting.
Vicarious Surgical Inc. is registering for resale up to 2,300,000 shares of Class A common stock issuable from Series A and Series B common warrants held by a single selling stockholder. The company is not offering any shares in this prospectus and will only receive cash if these $5.10 warrants are exercised for cash.
Class A common stock outstanding was 6,126,891 shares as of December 4, 2025, and would be 8,194,273 shares assuming full warrant exercise, illustrating the potential dilution if all warrants are exercised. The selling holder may sell shares over time in public or private transactions at market or negotiated prices.
Vicarious Surgical is developing a next-generation single-port robotic system for soft tissue surgery, which has not yet received FDA authorization. The company completed two controlled builds of its platform in 2025, targets a clinical-ready system by mid-2026 and first-in-human trials in 2027, and is operating under an NYSE compliance plan after previously falling below a $50 million market capitalization standard.
Vicarious Surgical Inc. is asking stockholders to approve the exercise of Common Warrants to purchase up to 2,300,000 shares of Class A common stock. These Series A and Series B Common Warrants, issued on October 7, 2025 with a cash exercise price of $5.10 per share and a five-year term starting on stockholder approval, were part of a registered direct offering and concurrent private placement that raised about $5.9 million in gross proceeds. If fully exercised for cash at the initial price, the warrants could bring in up to approximately $11.7 million in additional gross proceeds.
The approval is required under NYSE Rule 312.03(c) because the warrants cover more than 20% of the company’s outstanding common stock at a price below the NYSE “Minimum Price.” The company notes that it had cash and cash equivalents of about $3.2 million and short-term investments of about $10.3 million as of September 30, 2025, and views the potential proceeds as important to funding operations. If the proposal is approved and the warrants are exercised, existing holders would be diluted by the issuance of 2,300,000 additional Class A shares, and future sales of these shares could pressure the stock price.
Vicarious Surgical Inc. reported an insider share sale by a senior executive. On 12/03/2025, a reporting person who serves as Director, President and a 10% owner sold 463 shares of Class A common stock at a weighted average price of $2.952 per share. After this transaction, the insider directly beneficially owns 47,885 shares.
The company explains that the sale was executed solely to cover tax withholding obligations arising from the vesting of restricted stock units granted on June 2, 2023, under its equity incentive plan. The transaction was a mandatory “sell to cover” arrangement rather than a discretionary trade by the insider, and involved multiple trades at prices ranging from $2.715 to $3.34 per share.
FAQ
What is the current stock price of Vicarious Surgical (RBOT)?
What is the market cap of Vicarious Surgical (RBOT)?
